7,9-difluoro-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5H-6-oxa-chrysen-2-ol | 861931-21-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 7,9-difluoro-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5H-6-oxa-chrysen-2-ol
• 英文别名: 7,9-difluoro-5-[4-(2-piperidin-1-ylethoxy)phenyl]-5H-naphtho[1,2-c]chromen-2-ol
• CAS: 861931-21-7
• 化学式: C₃₀H₂₇F₂NO₃
• 分子量: 487.546
• InChiKey: AKRKKOYYGGSJRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  7,9-difluoro-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5H-6-oxa-chrysen-2-ol 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 以87%的产率得到7,9-difluoro-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5H-6-oxa-chrysen-2-ol hydrochloride salt
  参考文献：
  名称：

  [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS
  [FR] MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES POUR LE TRAITEMENT DE SYMPTOMES VASOMOTEURS

  摘要：

  本发明涉及一种公式I或Ia的选择性雌激素受体调节剂：(I) (Ia)；或其药物酸加成盐；用于治疗血管舒缩症状，尤其是热潮红、夜间出汗以及影响绝经前后妇女的其他症状。

  公开号：

  WO2005073204A1
• 作为产物：
  描述：

  5-{hydroxy-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methyl}-6-(2,3,5-trifluoro-phenyl)-naphthalen-2-ol 、 potassium tert-butylate 、 氯化铵 、 四氢呋喃 在 二氯甲烷 、 Sodium sulfate-III 作用下， 反应 3.0h， 以to yield 3.7 g (90%) of the title compound的产率得到7,9-difluoro-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5H-6-oxa-chrysen-2-ol
  参考文献：
  名称：

  Selective estrogen receptor modulators for the treatment of vasomotor symptoms

  摘要：

  本发明涉及式I或Ia的选择性雌激素受体调节剂：（I）（Ia）或其药物酸盐加合物；用于治疗血管运动症状，特别是影响绝经期妇女的潮热，夜间出汗和其他症状。

  公开号：

  US08217032B2

文献信息

• Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
  申请人：Wang Changjin

  公开号：US20100087402A1

  公开（公告）日：2010-04-08

  The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.

  本发明涉及治疗依赖雌激素的子宫过度增生性疾病，包括子宫内膜异位症、子宫肌瘤、子宫内膜增生、子宫癌及其相关症状，通过阴道给药至少两种活性药物，所选药物包括芳香化酶抑制剂、抗炎药和子宫选择性雌激素受体拮抗剂。这种联合疗法降低了局部雌激素产生，阻断了局部雌激素作用，并在局部抑制了炎症，导致对依赖雌激素的疾病组织的饥饿，缓解相关症状，延缓疾病进展。阴道给药最大限度地抑制了局部雌激素产生，而不显著影响全身循环雌激素水平。这导致增强的临床疗效和减少的副作用。
• Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
  申请人：Dally Robert Dean

  公开号：US20090023917A1

  公开（公告）日：2009-01-22

  The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.

  本发明涉及一种公式I或Ia的选择性雌激素受体调节剂：（I）（Ia）；或其药物酸加盐，用于治疗血管运动症状，特别是影响绝经期妇女的潮热、夜间盗汗和其他症状。
• SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS
  申请人：Dally Robert Dean

  公开号：US20110281847A1

  公开（公告）日：2011-11-17

  The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.

  本发明涉及公式I或Ia的选择性雌激素受体调节剂：（I）（Ia）或其医药酸盐，用于治疗血管运动症状，特别是影响绝经期妇女的潮热，夜间盗汗和其他症状。
• Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders
  申请人：Vivus, Inc.

  公开号：US20140080794A1

  公开（公告）日：2014-03-20

  The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.
• US8217032B2
  申请人：——

  公开号：US8217032B2

  公开（公告）日：2012-07-10